<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606889</url>
  </required_header>
  <id_info>
    <org_study_id>1072.6120.107.2018</org_study_id>
    <nct_id>NCT03606889</nct_id>
  </id_info>
  <brief_title>Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia</brief_title>
  <official_title>Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, the uses of peripheral axial blocks that deliver local anesthetic into the
      transversus abdominis fascial plane have become popular for operations that involve
      incision(s) of the abdominal wall. Thus, the Transversus Abdominis plane (TAP) block has been
      shown to reduce perioperative opioid use in elective abdominal surgery, including open
      appendicectomy, laparotomy, and laparoscopic cholecystectomy.

      Currently, the Quadratus Lumborum block (QL block) is performed as one of the perioperative
      pain management procedures for all generations (pediatrics, pregnant, and adult) undergoing
      abdominal surgery. The local anesthetic injected via the approach of the posterior QL block (
      QL 2 block ) can more easily extend beyond the TAP to the thoracic paravertebral space or the
      thoracolumbar plane, the posterior QL block entails a broader sensory-level analgesic and may
      generate analgesia from T7 to L1. Use of posterior QL block in laparoscopic prostatectomy has
      not been investigated before and it is the variant that will be discussed in our study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In laparoscopic prostatectomy, overall pain is a conglomerate of three different and
      clinically separate components: incisional pain (somatic pain), visceral pain (deep intra
      abdominal pain), and shoulder pain due to peritoneal stretching and diaphragmatic irritation
      associated with carbon dioxide insufflation. Moreover, it has been hypothesized that intense
      acute pain after laparoscopic prostatectomy may predict development of chronic pain. Without
      effective treatment, this ongoing pain may delay recovery, mandate inpatient admission, and
      thereby increase the cost of such care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total oxycodone used in the first 24 hours after surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>Total cumulative oxycodone dose in mg used in the first 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of postoperative pain via visual analogue pain scale (VAS)</measure>
    <time_frame>24 hours</time_frame>
    <description>VAS range from 0 for no pain to 10 for worst pain imaginable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostatic Cancer</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Pain</condition>
  <condition>Anesthetics, Local</condition>
  <arm_group>
    <arm_group_label>Quadratus Lumborum block group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transversus abdominis plane block group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quadratus Lumborum block</intervention_name>
    <description>0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle</description>
    <arm_group_label>Quadratus Lumborum block group</arm_group_label>
    <other_name>QLB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tranversus Abdominis plane block</intervention_name>
    <description>0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.</description>
    <arm_group_label>Transversus abdominis plane block group</arm_group_label>
    <other_name>TAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.2 ml/kg bupivicaine</description>
    <arm_group_label>Quadratus Lumborum block group</arm_group_label>
    <arm_group_label>Transversus abdominis plane block group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pateints who will have prostatectomy ASA II or III

        Exclusion Criteria: Patient refusal Local infection at the site of injection Allergy to
        study medications Sepsis Anatomic abnormalities Systemic anticoagulation or coagulopathy
        Inability to comprehend or participate in pain scoring system Inability to use intravenous
        patient controlled analgesia

        -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate is only in males.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Skladzien, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomasz Skladzien, MD PHD</last_name>
    <phone>506602250</phone>
    <phone_ext>+48</phone_ext>
    <email>t.skladzien@interia.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital in Cracow</name>
      <address>
        <city>Krak√≥w</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Skladzien, PhD</last_name>
      <phone>506602250</phone>
      <phone_ext>+48</phone_ext>
      <email>t.skladzien@interia.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Tomasz Skladzien</investigator_full_name>
    <investigator_title>MD PHD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

